Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses a Phase Ib study (NCT03400176) of ianalumab, a monoclonal antibody targeting the B-cell activating factor receptor, plus ibrutinib in patients with chronic lymphocytic leukemia (CLL). The study found that ianalumab plus ibrutinib had an acceptable safety profile and showed promising preliminary activity in patients with relapsed or refractory CLL on ibrutinib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.